Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.

<h4>Background</h4>The Study of Aldesleukin with and without antiretroviral therapy (STALWART) evaluated whether intermittent interleukin-2 (IL-2) alone or with antiretroviral therapy (ART) around IL-2 cycles increased CD4(+) counts compared to no therapy.<h4>Methodology</h4>...

Full description

Saved in:
Bibliographic Details
Main Authors: Jorge A Tavel, INSIGHT STALWART Study Group, Abdel Babiker, Lawrence Fox, Daniela Gey, Gustavo Lopardo, Norman Markowitz, Nicholas Paton, Deborah Wentworth, Nicole Wyman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-02-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0009334&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849734918410600448
author Jorge A Tavel
INSIGHT STALWART Study Group
Abdel Babiker
Lawrence Fox
Daniela Gey
Gustavo Lopardo
Norman Markowitz
Nicholas Paton
Deborah Wentworth
Nicole Wyman
author_facet Jorge A Tavel
INSIGHT STALWART Study Group
Abdel Babiker
Lawrence Fox
Daniela Gey
Gustavo Lopardo
Norman Markowitz
Nicholas Paton
Deborah Wentworth
Nicole Wyman
author_sort Jorge A Tavel
collection DOAJ
description <h4>Background</h4>The Study of Aldesleukin with and without antiretroviral therapy (STALWART) evaluated whether intermittent interleukin-2 (IL-2) alone or with antiretroviral therapy (ART) around IL-2 cycles increased CD4(+) counts compared to no therapy.<h4>Methodology</h4>Participants not on continuous ART with > or = 300 CD4(+) cells/mm(3) were randomized to: no treatment; IL-2 for 5 consecutive days every 8 weeks for 3 cycles; or the same IL-2 regimen with 10 days of ART administered around each IL-2 cycle. CD4(+) counts, HIV RNA, and HIV progression events were collected monthly.<h4>Principal findings</h4>A total of 267 participants were randomized. At week 32, the mean CD4(+) count was 134 cells greater in the IL-2 alone group (p<0.001), and 133 cells greater in the IL-2 plus ART group (p<0.001) compared to the no therapy group. Twelve participants in the IL-2 groups compared to 1 participant in the group assigned to no therapy experienced an opportunistic event or died (HR 5.84, CI: 0.59 to 43.57; p = 0.009).<h4>Conclusions</h4>IL-2 alone or with peri-cycle HAART increases CD4(+) counts but was associated with a greater number of opportunistic events or deaths compared to no therapy. These results call into question the immunoprotective significance of IL-2-induced CD4(+) cells.<h4>Trial registration</h4>ClinicalTrials.gov NCT00110812.
format Article
id doaj-art-fff474632b3342f48fa59bd301fcac40
institution DOAJ
issn 1932-6203
language English
publishDate 2010-02-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-fff474632b3342f48fa59bd301fcac402025-08-20T03:07:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-02-0152e933410.1371/journal.pone.0009334Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.Jorge A TavelINSIGHT STALWART Study GroupAbdel BabikerLawrence FoxDaniela GeyGustavo LopardoNorman MarkowitzNicholas PatonDeborah WentworthNicole Wyman<h4>Background</h4>The Study of Aldesleukin with and without antiretroviral therapy (STALWART) evaluated whether intermittent interleukin-2 (IL-2) alone or with antiretroviral therapy (ART) around IL-2 cycles increased CD4(+) counts compared to no therapy.<h4>Methodology</h4>Participants not on continuous ART with > or = 300 CD4(+) cells/mm(3) were randomized to: no treatment; IL-2 for 5 consecutive days every 8 weeks for 3 cycles; or the same IL-2 regimen with 10 days of ART administered around each IL-2 cycle. CD4(+) counts, HIV RNA, and HIV progression events were collected monthly.<h4>Principal findings</h4>A total of 267 participants were randomized. At week 32, the mean CD4(+) count was 134 cells greater in the IL-2 alone group (p<0.001), and 133 cells greater in the IL-2 plus ART group (p<0.001) compared to the no therapy group. Twelve participants in the IL-2 groups compared to 1 participant in the group assigned to no therapy experienced an opportunistic event or died (HR 5.84, CI: 0.59 to 43.57; p = 0.009).<h4>Conclusions</h4>IL-2 alone or with peri-cycle HAART increases CD4(+) counts but was associated with a greater number of opportunistic events or deaths compared to no therapy. These results call into question the immunoprotective significance of IL-2-induced CD4(+) cells.<h4>Trial registration</h4>ClinicalTrials.gov NCT00110812.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0009334&type=printable
spellingShingle Jorge A Tavel
INSIGHT STALWART Study Group
Abdel Babiker
Lawrence Fox
Daniela Gey
Gustavo Lopardo
Norman Markowitz
Nicholas Paton
Deborah Wentworth
Nicole Wyman
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
PLoS ONE
title Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
title_full Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
title_fullStr Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
title_full_unstemmed Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
title_short Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
title_sort effects of intermittent il 2 alone or with peri cycle antiretroviral therapy in early hiv infection the stalwart study
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0009334&type=printable
work_keys_str_mv AT jorgeatavel effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT insightstalwartstudygroup effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT abdelbabiker effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT lawrencefox effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT danielagey effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT gustavolopardo effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT normanmarkowitz effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT nicholaspaton effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT deborahwentworth effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy
AT nicolewyman effectsofintermittentil2aloneorwithpericycleantiretroviraltherapyinearlyhivinfectionthestalwartstudy